Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer (ABC) and primary or acquired resistance to aromatase inhibitors (AIS):: Final results of phase II SAKK trial 21/00

被引：0
|
作者：
Zaman, Khalil
Paridaens, Robert
Hawle, Hanne
Nole, Franco
Wildiers, Hans
Fiche, Maryse
Dietrich, Daniel
Goldhirsch, Aron
Thuerlimann, Beat
Perey, Lucien
机构：
[1] Swiss Grp Clin Canc Res, Bern, Switzerland
[2] Catholic Univ, Dept Gen Med Oncol, Univ Hosp Gasthuisberg, Louvain, Belgium
[3] European Inst Oncol, Unit Med Care, Dept Med, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：77 / 77
页数：1
相关论文
共 50 条
  • [1] Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors:: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00)
    Perey, L.
    Paridaens, R.
    Hawle, H.
    Zaman, K.
    Nole, F.
    Wildiers, H.
    Fiche, M.
    Dietrich, D.
    Clement, P.
    Koeberle, D.
    Goldhirsch, A.
    Thuerlimann, B.
    ANNALS OF ONCOLOGY, 2007, 18 (01) : 64 - 69
  • [2] A phase II trial of low-dose estradiol in postmenopausal women with advanced breast cancer and acquired resistance to aromatase inhibition
    Zucchini, G.
    Armstrong, A. C.
    Wardley, A. M.
    Wilson, G.
    Misra, V.
    Seif, M.
    Ryder, W. D.
    Cope, J.
    Blowers, E.
    Howell, A.
    Palmieri, C.
    Howell, S. J.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 (18) : 2725 - 2731
  • [3] A phase II trial of low dose estradiol in postmenopausal women with advanced breast cancer and acquired resistance to an aromatase inhibitor.
    Howell, S. J.
    Self, M. W.
    Armstrong, A. C.
    Cope, J.
    Wilson, G.
    Welch, R. S.
    Misra, V.
    Ryder, D.
    Blowers, E.
    Palmieri, C.
    Wardley, A. M.
    CANCER RESEARCH, 2012, 72
  • [4] Phase II Trial of Exemestane in Combination With Fulvestrant in Postmenopausal Women With Advanced, Hormone-Responsive Breast Cancer
    Mrozek, Ewa
    Layman, Rachel
    Ramaswamy, Bhuvaneswari
    Schaaf, Larry
    Li, Xiaobai
    Ottman, Susan
    Shapiro, Charles L.
    CLINICAL BREAST CANCER, 2012, 12 (02) : 151 - 156
  • [5] FULVESTRANT AS FIRST-LINE TREATMENT FOR ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN AFTER PROGRESSION ON PRIOR ADJUVANT THERAPY WITH THIRD-GENERATION AROMATASE INHIBITORS: A PHASE II TRIAL
    Palumbo, R.
    Bernardo, A.
    Strada, M. R.
    Teragni, C.
    Poggi, G.
    Frascaroli, M.
    Jedrychowska, I.
    Amatu, A.
    Bernardo, G.
    ANNALS OF ONCOLOGY, 2008, 19 : 71 - 71
  • [6] Fulvestrant (Faslodex™) as hormonal treatment in postmenopausal patients with advanced breast cancer (ABC) progressing after treatment with tamoxifen and non-steroidal aromatase inhibitors:: An ongoing phase IISAKK trial
    Perey, L
    Thürlimann, B
    Hawle, H
    Bonnefoi, O
    Aebi, S
    Dietrich, D
    Goldhirsch, A
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S98 - S98
  • [7] Fulvestrant (Faslodex™) as hormonal treatment in postmenopausal patients with advanced breast cancer progressing after treatment with tamoxifen and aromatase inhibitors:: update of a phase IISAKK trial
    Perey, VL
    Paridaens, R
    Nolé, F
    Bonnefoi, H
    Aebi, S
    Dietrich, D
    Goldhirsch, A
    Thürlimann, B
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S236 - S236
  • [8] Phase II trial of exemestane in combination with fulvestrant in postmenopausal women with hormone responsive advanced breast cancer: no evidence of a pharmacokinetic interaction between exemestane and fulvestrant.
    Mrozek, E.
    Schaaf, L. J.
    Ramaswamy, B.
    Shiels, D.
    Houton, L.
    Shapiro, C. L.
    CANCER RESEARCH, 2009, 69 (02) : 387S - 387S
  • [9] Activity of megestrol acetate in postmenopausal women with advanced breast cancer after nonsteroidal aromatase inhibitor failure: a phase II trial
    Bines, J.
    Dienstmann, R.
    Obadia, R. M.
    Branco, L. G. P.
    Quintella, D. C.
    Castro, T. M.
    Camacho, P. G.
    Soares, F. A.
    Costa, M. E. F.
    ANNALS OF ONCOLOGY, 2014, 25 (04) : 831 - 836
  • [10] A Phase II clinical trial to assess the efficacy and safety of 0.005% estriol Vaginal gel in hormone receptor-positive postmenopausal women with early stage breast cancer in treatment with Aromatase Inhibitors (AIs)
    Linden Hirschberg, Angelica
    Presa Lorite, Jesus
    Sanchez Rovira, Pedro
    Campos Delgado, Miriam
    Conde Iglesias, Carmen
    Fernandez Chereguini, Maria
    Zolfaroli, Irene
    Sanchez Vigil de la Villa, Isabel
    Suarez Almarza, Javier
    Nieto Magro, Concepcion
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2017, 24 (12): : 1430 - 1430
12345